莫西沙星与左氧氟沙星治疗下呼吸道感染的药物经济学评价

Pharmacoeconomic Evaluation on Moxifloxacin and Levofloxacin for the Treatment in Lower Respiratory Tract Infection

目的:对莫西沙星和左氧氟沙星治疗下呼吸道感染进行经济学评价。方法:根据文献选择下呼吸道感染病人98例,随机分成莫西沙星组(A)组和左氧氟沙星组(B)组,分别给予治疗。运用药物经济学的成本效果分析方法进行分析评价。结果:A组和B组治疗有效率分别为93.88%和89.80%,成本效果比(C/E)分别为23.99和7.84,ADR发生率分别为10.20%和8.16%,细菌清除率分别为97.37%和91.18%。结论:2组方案治疗下呼吸道感染的临床有效率与治愈率无显著差异,但A组的细菌清除率优于B组,B组的经济学成本优于A组。

Objective： To evaluate the economic effect of moxifloxacin injection and levofloxacin injection in treating lower respiratory tract infection. Methods： According to literature, 98 patients were chosen and divided randomly into team A （moxifloxacin） and team B（levofloxacin）. These two categories of patierits were given separate treatments which were analyzed and appraised by the cost-effect method in pharmacoeconomic research. Results： The overall clinical effective rate for team A is 93.88% and for team B is 89.80%. Occurrence of the adverse reaction for team A is 10.20% and for B is 8.16% and the bacterial clearance rate for team A is 97.37% and for team B is 91.18%. Conclusion： By these two kinds of treatment, there is no significant difference in clinical effective rate and cure rate for lower respiratory tract infection. However the bacterial clearance rate of team A is better than that of team B, and economic cost of team B is better than that of team A.